Feb 27 |
Denali, fresh off study setback, gets $500M lift
|
Feb 16 |
Denali slips as Sanofi fails in mid-stage trial for ALS therapy
|
Feb 16 |
UPDATE 1-Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial
|
Feb 16 |
ALS drug from Denali, Sanofi falls short in mid-stage study
|
Feb 7 |
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
|
Feb 1 |
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
|
Jan 26 |
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
|
Jan 11 |
40 Cities with the Lowest Life Expectancy in the US
|
Jan 8 |
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
|
Jan 2 |
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
|